Vaccines in RCC: Clinical and Biological Relevance

摘要: In 2014, renal cell carcinoma (RCC) accounted for nearly 4 % of all newly diagnosed cancers and 13,860 deaths in the United States (American Cancer Society, http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf 2014). While majority RCC patients are with localized disease an expected 5-year survival rate 92 %, 20–30 cases present as metastatic which is only 12 Following nephrectomy, has proven to be resistant conventional chemotherapy radiation therapy, necessitating further development targeted therapeutics including immunotherapies that may applied both adjuvant advanced-stage settings. this chapter, we will discuss state-of-the-art vaccination approaches treating burgeoning combination vaccine protocols optimally promote anti-RCC immunity association sustained clinical benefit(s).